DKK 728.0
(2.82%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | -49.41 Million DKK | -628.56% |
2022 | 7.77 Million DKK | -91.24% |
2021 | 88.78 Million DKK | 490.06% |
2020 | 15.04 Million DKK | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q1 | -12.92 Million DKK | -1.3% |
2024 Q2 | -12.92 Million DKK | 0.0% |
2023 Q1 | -11.4 Million DKK | -11.76% |
2023 FY | -41.11 Million DKK | -628.56% |
2023 Q3 | -12.42 Million DKK | -8.97% |
2023 Q2 | -11.4 Million DKK | 0.0% |
2023 Q4 | -12.76 Million DKK | -2.67% |
2022 Q2 | -4.51 Million DKK | 0.0% |
2022 Q1 | -4.51 Million DKK | 0.0% |
2022 FY | 7.77 Million DKK | -91.24% |
2022 Q3 | -10.2 Million DKK | -126.29% |
2022 Q4 | -10.2 Million DKK | 0.0% |
2021 FY | 88.78 Million DKK | 490.06% |
2020 FY | 15.04 Million DKK | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
ALK-Abelló A/S | 666 Million DKK | 107.42% |
Bavarian Nordic A/S | 1.49 Billion DKK | 103.3% |
Genmab A/S | 5.32 Billion DKK | 100.929% |
Novo Nordisk A/S | 102.57 Billion DKK | 100.048% |
Orphazyme A/S | -27.04 Thousand DKK | -182648.419% |
Pharma Equity Group A/S | -25.29 Million DKK | -95.378% |
Zealand Pharma A/S | -572.23 Million DKK | 91.364% |